

This is a disclosure report of your financial relationships with for-profit health care companies. Please keep your disclosure current and visit coi.asco.org to make any updates or revisions.

All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution

Employment

No Relationships to Disclose

Leadership

Company: Capio BioSciences

Recipient: An Immediate Family Member

Stock and Other Ownership Interests

Company: Capio Biosciences

Recipient: An Immediate Family Member

Company: Archimmune Therapeutics

Recipient: An Immediate Family Member

Honoraria

Company: Exelixis

Recipient: You

Company: Genentech/Roche

Recipient: You

Company: MJH Life Sciences

Recipient: You

Consulting or Advisory Role

Company: Janssen

Recipient: You

Company: Genentech/Roche

Recipient: You

Company: Sanofi

Recipient: You

Company: Exelixis

Recipient: You

Company: AstraZeneca

Recipient: You

Company: Pfizer

Recipient: You

Company: Bristol-Myers Squibb

Recipient: You

Company: Foundation Medicine

Recipient: You

Company: Pharmacyclics

Recipient: You

Company: Amgen

Recipient: You

Company: Merck

Recipient: You

Company: Seattle Genetics

Recipient: You

Speakers' Bureau

Company: Exelixis

Recipient: You

Company: Genentech/Roche

Recipient: You

Company: Genomic Health

Recipient: You

Company: Sanofi/Aventis

Recipient: You

Research Funding

Company: Janssen

Recipient: Your Institution

Company: Acerta Pharma

Recipient: Your Institution

Company: Pfizer

Recipient: Your Institution

Company: Merrimack
Recipient: Your Institution

Company: Stem CentRx
Recipient: Your Institution

Company: Novartis
Recipient: Your Institution

Company: OmniSeq
Recipient: Your Institution

Company: Personal Genome Diagnostics
Recipient: Your Institution

Company: Regeneron
Recipient: Your Institution

Company: Merck
Recipient: Your Institution

Company: Mirati Therapeutics
Recipient: Your Institution

Patents, Royalties, Other Intellectual Property

Company: Circulating tumor cell novel capture by c-MET technology
Recipient: Your Institution

Company: Prochelators as Targeted Prodrugs for Prostate Cancer
Recipient: Your Institution

Expert Testimony

No Relationships to Disclose

Travel, Accommodations, Expenses

Company: Acerta Pharma
Recipient: You

Company: Genomic Health
Recipient: You

Company: AstraZeneca
Recipient: You

Other Relationship

No Relationships to Disclose

(OPTIONAL) Uncompensated Relationships

No Relationships to Disclose

(OPTIONAL) Open Payments Link

No Relationships to Disclose
